OncLive TV

Jorge M. Mercado, MD, discusses the evolution of biopsy techniques in patients with lung cancer.

Ruth M. O’Regan, MD, discusses the significance of the Breast Cancer Index as a prognostic tool, as well as the investigation of the phase 3 SOFT trial for patients with early-stage, hormone receptor-positive breast cancer.

Erica L. Mayer, MD, MPH, discusses findings from the phase 2 PACE trial in patients with hormone receptor (HR)–positive/HER2-negative metastatic breast cancer.

Rachel Jimenez, MD, discusses the management of toxicities associated with radiotherapy for patients with breast cancer.

Mridula George, MD, discusses the evaluation of cardiotoxicity associated with adjuvant trastuzumab emtansine with concurrent radiotherapy in patients with HER2-positive breast cancer.

Christina Wu, MD, discusses key targeted therapies under investigation in patients with colorectal cancer.

Max S. Topp, MD, discusses the safety profile of glofitamab in combination with R-CHOP in patients with diffuse large B-cell lymphoma.

Mohamad Ezzeddine Allaf, MD, discusses several key considerations when interpreting and extrapolating initial results from the phase 3 PROSPER-RCC trial in renal cell carcinoma.

Tanya Dorff, MD, discusses the investigation of PARP inhibitors in metastatic castration-resistant prostate cancer.

Peter Kozuch, MD, discusses the phase 2/3 CIRCULATE-US trial evaluating chemotherapy decisions for patients with resected colorectal cancer based on circulating tumor DNA status.

Manmeet Singh Ahluwalia, MD, discusses the evaluation of SurVaxM in combination with oral temozolomide in patients with newly diagnosed glioblastoma.

Jeremy Force, DO, discusses the efficacy of trastuzumab deruxtecan in pretreated patients with HER2-positive breast cancer on the phase 3 DESTINY-Breast02 trial.

Sapna Patel, BA, MD, discusses the sequencing of immunotherapy and targeted therapy in BRAF-mutant melanoma.

Rupert Bartsch, MD, discusses interim findings produced from the real-world use of neratinib in select patients with hormone receptor-positive, HER2-overexpressed breast cancer.

Carsten Niemann, MD, PhD, discusses notable data on patient survival outcomes, as well as the impact of minimal residual disease in the peripheral blood from the phase 3 GLOW trial in patients with chronic lymphocytic leukemia.

Carlo Contreras, MD, discusses the role of neoadjuvant pembrolizumab for the treatment of patients with desmoplastic melanoma.

Jeanny B. Aragon-Ching, MD, FACP, discusses the use of maintenance avelumab as the standard-of-care treatment for patients with locally advanced or metastatic urothelial carcinoma.

Maryam Lustberg, MD, MPH, discusses the real-world use of ovarian suppression therapy in clinical practice for premenopausal patients with hormone receptor-positive, HER2-positive breast cancer.

Megan Kruse, MD, discusses how socioeconomic disparities and access to health insurance can contribute to poorer overall survival (OS) outcomes in adolescent patients with invasive breast cancer.

Joseph Alvarnas, MD, discusses the importance of access to CAR T-cell therapy in cancer care.

Sanjeet Singh Dadwal, MD, discusses the investigation of posoleucel as a prevention strategy for infections in patients following an allogenic hematopoietic cell transplant.

Johannes Zakrzewski, MD, discusses the investigation of a nanoframework-based delivery system for IT848 in hematologic malignancies.

Claire F. Verschraegen, MD, discusses the need for predictive biomarkers for the use of immunotherapy in the treatment of melanoma.

Jane L. Meisel, MD, discusses the effect of the HER2-low classification for patients with breast cancer.

Tanya Dorff, MD, discusses remaining questions regarding sequencing in metastatic renal cell carcinoma.

Craig Sauter, MD, discusses important considerations regarding the use of pembrolizumab after autologous stem cell transplant in T-cell non-Hodgkin lymphoma.

Vamsidhar Velcheti, MD, discusses the evaluation of immunotherapy combination regimens for patients with metastatic non–small cell lung cancer.

Al-Ola A. Abdallah, MD, discusses interim results from an ongoing phase 1 trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma.

Carmelo Carlo-Stella, MD, PhD, discusses updated results from a phase 1 dose-escalation study of subcutaneous and intravenous RG6234 in relapsed/refractory multiple myeloma.

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss second-line treatment options for patients with non—small cell lung cancer who progressed on first-line EGFR-directed tyrosine kinase inhibitors.